Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000232110 is a human long non-coding RNA (lncRNA) gene annotated as "novel transcript, antisense to LIPA" and also known by the locus identifier LOC124902477. It is transcribed in the opposite orientation to the LIPA gene—an enzyme involved in cholesterol metabolism—but does not code for a protein itself. lncRNAs of this type are often involved in regulating their sense gene counterparts at the RNA or chromatin level through mechanisms such as RNA masking, transcriptional interference, or the production of double-stranded RNA that can participate in regulatory or silencing pathways[1][5]. However, there is no direct evidence to date defining the exact biological function or disease relevance of ENSG00000232110 specifically. It is not considered a therapeutic target or biomarker in clinical or translational research databases. This target follows standard naming conventions as a non-protein-coding RNA, with no functional data linking it to disease or drug action at present[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to LIPA (ENSG00000232110 (or LOC124902477, as used in some databases)).